Fort Worth Stock Show and Rodeo's Grand Champion Steer auctioned for $375K
The Fort Worth Stock Show and Rodeo's Youth Auction was Saturday.
Grand Champion Steer Alley Cat was auctioned for $375K.
More than $10 million was spent at the Youth Auction this year.
FORT WORTH, Texas - The Grand Champion Steer at this year's Fort Worth Stock Show and Rodeo was auctioned off for $375,000 on Saturday.
The 2025 grand champion steer is a silver American Cross named Alley Cat.
Vaden's Acoustics & Drywall, Inc. placed the winning $375,000 bid in the auction at Watt arena.
Alley Cat's owner is 16-year-old Mattison Koepp, of La Vernia, Texas, near San Antonio.
The Reserve Grand Champion Steer, shown by Bricelyn Patschke of Idalou, Texas, was auctioned off for $300,000.
By the numbers
More than $10 million was raised in the Stock Show's Youth Auction.
That is approximately $1.8 million more than last year.
What they're saying
"Our amazing buyers at the Junior Sale of Champions make a tremendous investment in these incredible youth that participate in our show," said Stock Show General Manager Matt Carter. "A huge thank you to the Fort Worth community that supports these young men and women who will make sure tomorrow's livestock industry and food security is in good hands."
The Source
Information in this article comes from the Fort Worth Stock Show and Rodeo and past FOX 4 coverage.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the 'Company' or 'VivoSim Labs'), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development. Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024. Services represented 53.1% of revenue vs. models at 46.9% of revenue. The United States accounted for $325M (50.8%) of the global market for liver toxicology models and services. Adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at 5.9% CAGR from 2020 to 2024. Category Tailwinds: Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology. How AI Helps: VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence. 'VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,' said Tony Lialin, Chief Commercial Officer, VivoSim Labs. 'We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises.' 'Tony has a rare track record of turning disruptive science into durable commercial engines,' said Keith Murphy, Executive Chairman, VivoSim Labs. 'As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need.' About VivoSim Labs VivoSim Labs, Inc. ("VivoSim" and the 'Company'), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ('FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company's San Diego-based services; the potential for the Company's organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company's services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. ContactInvestor Relationsinfo@ Labs, in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Bath & Body Works to Report Second Quarter Results on August 28, 2025
COLUMBUS, Ohio, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE: BBWI) announced today that it plans to report its second quarter 2025 financial results before market open on Thursday, August 28, 2025. In conjunction with this report, the company will host a conference call at 8:30 a.m. ET during which Daniel Heaf, chief executive officer, and Eva Boratto, chief financial officer, will discuss the company's results and provide a business update. Supplemental materials will be posted approximately 90 minutes prior to the start of the conference call on the events and presentations page in the Investors section of the company's website at Investors and analysts interested in participating in the conference call are invited to dial 877-407-9219 (domestic) or 412-652-1274 (international). A telephone replay of the conference call can be accessed by dialing 877-660-6853 (domestic) or 201-612-7415 (international) and entering access code 13754889. To listen to the audio webcast, please visit the events and presentations page in the Investors section of the company's website at The webcast replay will be available approximately three hours following the live call and archived for 90 days. ABOUT BATH & BODY WORKS: Home of America's Favorite Fragrances®, Bath & Body Works is a global leader in personal care and home fragrance, including top-selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap. Powered by agility and innovation, the company's predominantly U.S.-based supply chain enables it to deliver quality, on-trend luxuries at affordable prices. Bath & Body Works serves and delights customers however and wherever they want to shop, from welcoming, in-store experiences at 1,900 Company-operated Bath & Body Works locations in the U.S. and Canada, 524 international franchised locations and an online storefront at (as of May 3, 2025). For further information, please contact: Bath & Body Works:Investor RelationsLuke Longinvestorrelations@ Media RelationsEmmy Beachcommunications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Cloudflare, Inc. (NET) Reports Second-Quarter Results; Scotiabank Raises PT to $200
Cloudflare, Inc. (NYSE:NET) is included in our list of the 11 Hot Software Stocks to Buy Now. A close-up of a hand tapping away at a keyboard, using the company's software to carry out a transaction. On August 1, 2025, Scotiabank raised its price target on Cloudflare, Inc. (NYSE:NET) from $135 to $200, maintaining a 'Sector Perform' rating. This price revision came a day after the company reported its second-quarter results. For Q2, Cloudflare, Inc. (NYSE:NET) reported annualized revenue of over $2 billion with 28% YoY growth. Its revenue reached $512.3 million, which exceeded expectations. Furthermore, its non-GAAP operating income reached $72.3 million, bringing the margin to 14.1%. Cloudflare, Inc. (NYSE:NET)'s leadership cited stronger demand, larger and longer-term deals, and strategic wins in AI-driven content creator solutions. The company is well-positioned to capitalize on the emerging 'agentic web,' a new phase of the internet marked by autonomous, goal-driven interactions. With gross margins of 76.3%, Cloudflare, Inc. (NYSE:NET) closed the quarter with approximately $4 billion in cash. Looking ahead, it expects FY25 revenue of $2.113-$2.116 billion and Q3 revenue of $544.5 million on the higher side. With its vast connectivity cloud platform, Cloudflare, Inc. (NYSE:NET) delivers cloud-based networking, security, and performance solutions. It is included in our list of the hot stocks to buy. While we acknowledge the potential of NET as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Oil Refinery Stocks to Buy Right Now and 7 Best Potash Stocks to Buy According to Analysts. Disclosure: None.
